Evaluating antitumor effect of a novel hydrazide derivative in mammalian mice model

One of the major problems of breast cancer is unwanted side effects and tumor resistance to the available chemotherapeutics. Therefore, there is always a need toward finding new anticancer agents with limited toxicity and less multidrug resistance of cancer cells. Literature studies on hydrazones have shown that these derivatives have a wide variety of biological activities including antitumoral effects. Thus, the aim of this study was to examine the antitumor effect of a novel hydrazide derivative [2- (phenlthoi) benzoid acid (5-nitor-2-furyline) hydrazid (Compound A)] in mammalian mice model.
We injected 106 4T1 cells into mammary fat pad of 6-8 week old female BALB/c mice to establish the syngenic breast cancer model. Following, the apperance of brerast tumors, the compound A was injected (i.p.) at doses of 1, 10 and 50 mg/kg per days for three weeks.
ung metastasis was observed after 28 days of cell injection, which was confirmed by histopathological experiments. Compound A treated mice group significantly reduced primary tumor growth at all tested doses; however, the dose of 10 mg/kg was the most effective in reducing the tumor size. Histopathologic data showed that the regression of tumor growth was associated with extensive inflammation. The dose of 10 mg/kg compound A reduced size of secondary lung tumor and caused necrosis.
Collectively, the great potential exhibited by compound A could make it a promising chemotherapeutic candidate for breast cancer.